Infectious Disease Molecular Diagnostics Market to Record 5% CAGR Growth Through 2029 | Global Analysis Report

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

Infectious Disease Molecular Diagnostics Market Outlook: How is the Market Expected to Grow by 2025?
In the past few years, there has been a significant expansion in the market size of infectious disease molecular diagnostics. It is projected to grow from $28.95 billion in 2024 to $30.46 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. Such growth during the historic period is primarily driven by an increasing number of cases of infectious diseases, an increased need for accurate and early diagnosis, global outbreaks and pandemics, the heightened availability and understanding of healthcare facilities, as well as increased funding in diagnostic research and technology.

Infectious Disease Molecular Diagnostics Market Forecast: What Size Will It Reach By 2029?
The market for molecular diagnostics in infectious diseases is projected to witness robust growth in coming years, escalating to a worth of $36.98 billion by the year 2029, with a compound annual growth rate (CAGR) of 5.0%. This anticipated growth within the forecast period can be ascribed to factors such as the growing use of point-of-care testing, heightened emphasis on personalized medicine, increased government involvement in infectious disease management, the development of healthcare facilities in emerging markets, and a higher incidence of respiratory ailments. The upcoming period predicts several trends, including progress in real-time polymerase chain reaction technology, improvements in the integration of artificial intelligence within diagnostic platforms, the creation of multiplex testing panels, innovations in portable and home-based diagnostic kits, and advancements in the automation of molecular diagnostic processes.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/infectious-disease-molecular-diagnostics-global-market-report

Which Key Market Drivers Will Shape Infectious Disease Molecular Diagnostics Industry Trends in 2025-2029?
The escalation in infectious diseases occurrences is projected to stimulate the expansion of the infectious disease molecular diagnostics market. These diseases, which include illnesses instigated by pathogenic microbes such as bacteria, viruses, fungi, or parasites, can be transmitted directly or indirectly from one person to another. The upward trend in infectious disease occurrences is primarily attributed to globalization and heightened travel, which gives pathogens the capability to rapidly disseminate across borders and transform localized epidemics into worldwide health crises. Infectious disease molecular diagnostics aid in infectious disease control by providing speedy, precise detection of pathogens at the genetic level. This favors early diagnosis, focused treatment, and efficient outbreak management. In November 2023, for example, the Centers for Disease Control and Prevention, a US government agency, noted that in 2022, the United States saw 8,331 tuberculosis (TB) cases. This signifies a 5.9% escalation in the number of cases when contrasted with 2021. Therefore, the upward trend in infectious disease occurrences is pushing the expansion of the infectious disease molecular diagnostics market forward.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25793&type=smp

What Are the High-Growth Segments in the Infectious Disease Molecular Diagnostics Market?
The infectious disease molecular diagnostics market covered in this report is segmented -

1) By Product Type: Kits And Reagents, Instruments, Software And Services
2) By Technology: Polymerase Chain Reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology, Chips And Microarrays, Mass Spectrometry, Transcription Mediated Amplification, Other Technologies
3) By Application: Respiratory Diseases, Tuberculosis, Meningitis, Gastrointestinal Tract Infections, Human Papillomavirus, Sexually Transmitted Infections, Sepsis, Drug Resistance Diseases, Other Applications
4) By End-User: Hospitals And Clinical Laboratories, Diagnostic Laboratories, Pharmaceutical Companies, Academic And Research Institutes

Subsegments:
1) By Kits And Reagents: Deoxyribonucleic Acid Or Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Isothermal Amplification Kits, Probe-Based Detection Reagents, Pathogen-Specific Assay Kits
2) By Instruments: Real-Time Polymerase Chain Reaction Systems, Isothermal Amplification Instruments, Automated Sample Preparation Systems, Next-Generation Sequencing Platforms, Microarray Analyzers
3) By Software And Services: Data Analysis And Interpretation Software, Laboratory Information Management Systems, Cloud-Based Infectious Disease Diagnostic Platforms, Instrument Integration And Workflow Management Tools, Bioinformatics Services

Which Global Trends Are Driving Infectious Disease Molecular Diagnostics Market Expansion?
Key players in the molecular diagnostics market for infectious diseases are concentrating on developing ground-breaking solutions, like real-time polymerase chain reaction kits, to facilitate swift, precise, and high-capacity detection of infectious microorganisms. These PCR kits are diagnostic instruments that magnify and concurrently identify specific genetic material from pathogens promptly, facilitating speedy and accurate detection of infectious diseases. For example, Thermo Fisher Scientific Inc., a biotechnology and life sciences firm from the US, launched the Applied Biosystems TaqPath polymerase chain reaction kits for detecting infectious diseases in India in February 2023. These kits are efficient and highly sensitive multiplex diagnostic tools that use a comprehensive process from extracting ribonucleic acid to generating diagnostic reports, mostly in less than 4 hours. These kits are equipped with multiplexed assays focusing on multiple genomic areas of microorganisms, consist of inbuilt process controls, and offer automated data interpretation, diminishing user mistakes and increasing the reliability of the results.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25793&type=smp

Who Are the Fastest-Growing Companies in the Infectious Disease Molecular Diagnostics Industry?
Major companies operating in the infectious disease molecular diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Agilent Technologies Inc., Hologic Inc., Illumina Inc., Biomerieux S.A., Quidel‐Ortho Corporation, Sysmex Corporation, Bio‐Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A., Seegene Inc., Oxford Nanopore Technologies plc, Biocartis NV, T2 Biosystems Inc., Sherlock Biosciences Inc.

What Is the Regional Outlook for the Infectious Disease Molecular Diagnostics Market by 2029?
North America was the largest region in the infectious disease molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.